Pancreatic Cancer Research

ResearcherSecond Hospital of Tianjin Medical UniversityNo recent work listed

Yanxun Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-4473-6138; OpenAlex author ID A5101921826. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: none · 2021: none · 2022: 1 paper

Papers 4

  1. N(6)-methyladenosine-mediated miR-380-3p maturation and upregulation promotes cancer aggressiveness in pancreatic cancer. Co-author DOI 10.1080/21655979.2022.2088497↗
  2. Aspirin use and pancreatic cancer risk: A systematic review of observational studies. First author DOI 10.1097/md.0000000000018033↗
  3. Downregulation of miR-21 inhibits the malignant phenotype of pancreatic cancer cells by targeting VHL. Co-author DOI 10.2147/ott.s211535↗
  4. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized cont… Co-author DOI 10.1179/1973947815y.0000000013↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhijia Jiang · 4 shared papers, 2015–2022 · strength 0.49
  2. Jinjin Sun · 3 shared papers, 2015–2019 · strength 0.30
  3. Geng Liu · 2 shared papers, 2015–2019 · strength 0.19
  4. Jinjin Sun · 1 shared paper, 2022 · strength 0.19
  5. Kaiqiang Wang · 1 shared paper, 2019 · strength 0.11
  6. Geng Liu · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.